Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | MTNB |
---|---|---|
09:32 ET | 1596 | 0.59 |
09:37 ET | 20267 | 0.624 |
09:50 ET | 1140 | 0.5876 |
09:53 ET | 300 | 0.5876 |
10:00 ET | 1400 | 0.5938 |
10:02 ET | 340 | 0.611 |
10:13 ET | 300 | 0.6011 |
10:15 ET | 2300 | 0.6 |
10:27 ET | 200 | 0.5931 |
10:31 ET | 286 | 0.5896 |
11:00 ET | 741 | 0.5895 |
11:12 ET | 100 | 0.599 |
11:18 ET | 1000 | 0.5897 |
11:27 ET | 769 | 0.599 |
11:36 ET | 5701 | 0.6 |
11:38 ET | 307 | 0.5999 |
11:52 ET | 129 | 0.5999 |
12:12 ET | 2000 | 0.5901 |
12:14 ET | 500 | 0.61 |
12:15 ET | 3900 | 0.611 |
12:17 ET | 243 | 0.6145 |
12:21 ET | 183 | 0.62 |
12:24 ET | 917 | 0.62 |
12:30 ET | 157 | 0.6033 |
12:33 ET | 400 | 0.6201 |
12:35 ET | 990 | 0.6147 |
12:39 ET | 286 | 0.6101 |
12:42 ET | 500 | 0.6101 |
12:53 ET | 1100 | 0.6101 |
01:06 ET | 100 | 0.6101 |
01:18 ET | 300 | 0.5991 |
01:22 ET | 1100 | 0.5991 |
01:24 ET | 600 | 0.591 |
01:26 ET | 1100 | 0.591 |
01:45 ET | 100 | 0.605 |
01:56 ET | 100 | 0.6 |
02:21 ET | 934 | 0.6 |
02:39 ET | 100 | 0.6 |
03:03 ET | 200 | 0.6001 |
03:08 ET | 200 | 0.610001 |
03:10 ET | 100 | 0.619 |
03:37 ET | 100 | 0.6102 |
03:53 ET | 100 | 0.61 |
04:00 ET | 532 | 0.6001 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Matinas BioPharma Holdings Inc | 3.1M | -0.1x | --- |
Kaleido Biosciences Inc | 4.3K | 0.0x | --- |
Azitra Inc | 3.7M | -0.1x | --- |
Biodexa Pharmaceuticals PLC | 2.7M | 0.0x | --- |
Oncternal Therapeutics Inc | 1.6M | 0.0x | --- |
Mymetics Corp | 150.0 | 0.0x | --- |
Matinas BioPharma Holdings, Inc. is a biopharmaceutical company. The Company is focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology (LNC Platform). Its lead product candidate is MAT2203 (oral amphotericin B), a highly potent antifungal drug which, by virtue of LNC delivery, has been made oral, safe, and well-tolerated for prolonged administration in patients with life-threatening invasive fungal infections. MAT2203 is now positioned for a single, Phase III registration trial (the ORALTO trial) in support of a New Drug Application (NDA) for the treatment of invasive aspergillosis in patients with limited treatment options. It is expanding the utilization of the LNC Platform with small molecules and small oligonucleotides outside of infectious disease, targeting inflammation and oncology. It is also investigating a variety of LNC formulations of two small oligonucleotides designed to target inflammatory cytokines IL-17A and TNFα.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $3.1M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 5.1M |
Matinas BioPharma Holdings Inc does not pay a dividend. | |
Beta | 1.59 |
EPS | $-4.56 |
Book Value | $4.43 |
P/E Ratio | -0.1x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.